Medicine & Life Sciences
Hodgkin Disease
100%
B-Cell Lymphoma
69%
Rituximab
56%
Lymphoma
43%
PCI 32765
42%
axicabtagene ciloleucel
40%
Mantle-Cell Lymphoma
40%
Radiotherapy
37%
Progression-Free Survival
34%
Lenalidomide
31%
Chimeric Antigen Receptors
31%
Survival
30%
Lymphoma, Large B-Cell, Diffuse
29%
Brentuximab Vedotin
28%
Nivolumab
27%
Drug Therapy
24%
Follicular Lymphoma
24%
Therapeutics
24%
pembrolizumab
21%
Recurrence
20%
Peripheral T-Cell Lymphoma
18%
Cell- and Tissue-Based Therapy
18%
T-Lymphocytes
17%
Neurotoxicity Syndromes
16%
Cyclophosphamide
16%
B-Cell Chronic Lymphocytic Leukemia
16%
Stem Cell Transplantation
16%
Doxorubicin
16%
Adoptive Immunotherapy
15%
Neoplasms
15%
Heterogeneous-Nuclear Ribonucleoprotein K
15%
Confidence Intervals
15%
Acute Myeloid Leukemia
14%
Safety
13%
Positron Emission Tomography Computed Tomography
13%
Vincristine
13%
Non-Hodgkin's Lymphoma
11%
Transplants
11%
Eye
11%
Dacarbazine
9%
Vinblastine
8%
Survival Rate
8%
Cytokine Release Syndrome
8%
Agammaglobulinaemia Tyrosine Kinase
8%
Graft vs Host Disease
8%
Survivors
8%
Salvage Therapy
8%
Phase II Clinical Trials
8%
Disease Progression
8%
Multicenter Studies
8%